|6th October 2020||John L Lamattina||46,388||Conversion of derivative||$0.00|
|24th August 2020||Matthew W Foehr||78||Open or private sale||$110.89||$8,649.42|
|24th August 2020||Matthew W Foehr||78||Exercise of derivative||$21.92||$1,709.76|
|21st August 2020||Matthew W Foehr||790||Exercise of derivative||$74.42||$58,791.80|
|21st August 2020||Matthew W Foehr||7,225||Exercise of derivative||$14.47||$104,545.75|
|21st August 2020||Matthew W Foehr||7,225||Open or private sale||$112.88||$815,540.66|
|18th August 2020||Todd C Davis||50,000||Open or private sale||$4.99||$249,500.00|
|7th August 2020||Todd C Davis||30,000||Exercise of derivative||$0.00|
|7th July 2020||John L Higgins||1,777||Exercise of derivative||$56.26||$99,974.02|
|7th July 2020||John L Higgins||1,165||Exercise of derivative||$85.79||$99,945.35|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987.